Intraperitoneal Therapy with Fluoropyrimidines in the Treatment of Ovarian and Gastrointestinal Cancers

摘要: Dose-effect relationships are the underlying rationale for exploring local-regional administration of drugs (1). The role dose-intensity (or, more specifically, dose-density) in improving results from chemotherapy solid tumors has been a subject frequent debate. Unfortunately, systemic most to relatively narrow range dose escalation, even with use myelopoietic growth factors ameliorate dose-limiting toxicities many common anticancer drugs. Moreover, accumulating clinical experience suggests that dose-effect beyond usual tolerance do not lead tangible evidence greater benefit increasing doses. For example, ovarian cancer (OC) trials testing platinum have almost uniformly disappointing (2,3). When disease is predominantly confined peritoneal cavity, however, dose-intensification (as defined by pharmacologic advantage expressed as intraperitoneal (ip) area under curve (AUC)/plasma AUC) achieved through ip varies severalfold several log-fold among various tested (4). This degree would be expected show enhanced effects, which such considered flat usually employed per cycle, described carboplatin (5).